May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Intravitreal Triamcinolone Acetonide in the Treatment of Serous Retinal Detachment in Vogt–Koyanagi–Harada Syndrome
Author Affiliations & Notes
  • C. Muccioli
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • R.E. Andrade
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • M.E. Farah
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • L. Peixoto
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • R.B. Nussenblatt
    Laboratory of Immunology, NEI, NIH, Bethesda, MI
  • R. Belfort Jr
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • Footnotes
    Commercial Relationships  C. Muccioli, None; R.E. Andrade, None; M.E. Farah, None; L. Peixoto, None; R.B. Nussenblatt, None; R. Belfort Jr, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 2677. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. Muccioli, R.E. Andrade, M.E. Farah, L. Peixoto, R.B. Nussenblatt, R. Belfort Jr; Intravitreal Triamcinolone Acetonide in the Treatment of Serous Retinal Detachment in Vogt–Koyanagi–Harada Syndrome . Invest. Ophthalmol. Vis. Sci. 2004;45(13):2677.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To report the use of intravitreal injection of triamcinolone acetonide (TAAC) at the acute phase of Vogt–Koyanagi–Harada's disease. Methods: Nine eyes from five patients at the acute phase of Vogt–Koyanagi–Harada's disease with serous retinal detachments were treated with a 4 mg intravitreal injection of TAAC. The following parameters were evaluated: visual acuity, intraocular pressure, as well as the height of the serous retinal detachment using optical coherence tomography (OCT). Results: OCT images showed a marked decrease in the retinal detachment in the first week after the injection with subsequent return to normal retinal thickness in all eyes. Follow–up ranged from 5 to 12 months with a mean of 7,8 months. No complications were observed. Conclusions: Intravitreal TAAC provides short–term improvement in visual acuity and serous retinal detachments associated with Vogt–Koyanagi–Harada's disease. These findings should be followed by future studies to evaluate long term effects.

Keywords: imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • injection • retinal detachment 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×